Posted by Michael Wonder on 19 May 2017
Sage Therapeutics receives fast track designation for SAGE-217 for the treatment of major depressive disorder
18 May 2017 - Sage Therapeutics today announced that the U.S. FDA has granted fast track designation to SAGE-217 for development as a potential treatment for major depressive disorder.
Fast Track is a process designed to facilitate the development and review of new treatments for serious conditions with unmet medical need such as major depressive disorder.
